Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Prostate Neoplasms
Interventions: Abiraterone acetate, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Testosterone Deficiency, Hypogonadism, Male
Interventions: Testosterone; Drug
Lead sponsor: Men's Health Boston; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: ESK981; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Detroit, Michigan • Seattle, Washington

Conditions: Heart Failure
Interventions: placebo, testosterone; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Phoenix, Arizona • Tucson, Arizona • Lakewood, California + 13 more

Conditions: Prostate Cancer
Interventions: AndroGel, placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Aging, Testosterone Deficiency
Interventions: AlphaFen fenugreek 400 mg, AlphaFen fenugreek 500 mg, Placebo; Dietary Supplement · Other
Lead sponsor: Jacksonville University; Other
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer
Interventions: Goserelin, Enzalutamide, mpMRI; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hot Flashes
Interventions: Isoflavone, Placebos; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypogonadism, Male
Interventions: SOV2012-F1; Drug
Lead sponsor: Marius Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 19
States / cities: Birmingham, Alabama • Mobile, Alabama • Aventura, Florida + 16 more

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: Testosterone Enanthate, Somatropin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Testosterone Deficiency
Interventions: Testosterone Therapy; Drug
Lead sponsor: Men's Health Boston; Other
Eligibility: 20 Years to 90 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Healthy
Interventions: Nestorone® /testosterone gel, Testosterone only gel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypogonadism
Interventions: Testopel 75mg Drug Implant, Testopel 100mg Drug Implant, Testopel 200mg Drug Implant; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Male Hypogonadism
Interventions: Oral testosterone undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 27
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more

Conditions: Hypogonadism
Interventions: testosterone; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 20 Years to 60 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Torrance, California

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions: Testosterone Enanthate, Locomotor Training; Drug · Behavioral
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Castration Resistant Metastatic Prostate Cancer
Interventions: Testosterone cypionate, Enzalutamide, Testosterone enanthate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions: Enzalutamide, Laboratory Biomarker Analysis, Niclosamide, Pharmacological Study; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypogonadism
Interventions: AndroGel 1.62%; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 45
States / cities: Foley, Alabama • Newport Beach, California • Northridge, California + 40 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Testosterone Deficiency
Interventions: Clomiphene Citrate 25mg, Clomiphene Citrate 50mg; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 45 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Insulin Resistance
Interventions: Ketoconazole, Hydrocortisone, Testosterone, Placebo for ketoconazole, Placebo for hydrocortisone, Placebo for testosterone; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hypogonadism
Interventions: Testosterone Cypionate; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Houston, Texas

Search by objective public record fields.

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Subcutaneous vs. Intramuscular Testosterone

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

The Efficacy of Fenugreek Supplementation on Men's Health

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

Study of Testosterone and rHGH in FSHD

Metabolomics During Testosterone Therapy

Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men

The COSMYC Trial (COmbined Suppression of MYC)

Testopel ® vs. Generic Testosterone Pellets.

Safety and Efficacy Trial of Testosterone Undecanoate

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate

Hormonal Mechanisms of Sleep Restriction

CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy